PT  - JOURNAL ARTICLE
AU  - Blankman, Jacqueline L.
AU  - Cravatt, Benjamin F.
ED  - Barker, Eric L.
TI  - Chemical Probes of Endocannabinoid Metabolism
AID  - 10.1124/pr.112.006387
DP  - 2013 Apr 01
TA  - Pharmacological Reviews
PG  - 849--871
VI  - 65
IP  - 2
4099  - http://pharmrev.aspetjournals.org/content/65/2/849.short
4100  - http://pharmrev.aspetjournals.org/content/65/2/849.full
SO  - Pharmacol Rev2013 Apr 01; 65
AB  - The endocannabinoid signaling system regulates diverse physiologic processes and has attracted considerable attention as a potential pharmaceutical target for treating diseases, such as pain, anxiety/depression, and metabolic disorders. The principal ligands of the endocannabinoid system are the lipid transmitters N-arachidonoylethanolamine (anandamide) and 2-arachidonoylglycerol (2-AG), which activate the two major cannabinoid receptors, CB1 and CB2. Anandamide and 2-AG signaling pathways in the nervous system are terminated by enzymatic hydrolysis mediated primarily by the serine hydrolases fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), respectively. In this review, we will discuss the development of FAAH and MAGL inhibitors and their pharmacological application to investigate the function of anandamide and 2-AG signaling pathways in preclinical models of neurobehavioral processes, such as pain, anxiety, and addiction. We will place emphasis on how these studies are beginning to discern the different roles played by anandamide and 2-AG in the nervous system and the resulting implications for advancing endocannabinoid hydrolase inhibitors as next-generation therapeutics.